nhia logo

Quick Links
Search NHIA.org



Counce JB. Amgen: Science-based, patient-driven, provider-friendly;8(5):29-31.

Davydov L. Biosimilars and other drugs in today's development pipeline. 2016;22(5):S1-S16.

Deitz-Lovett K. Managing chemotherapy-induced anemia: Supportive care plan for home infusion therapy. 2006.12(6):S1-S8.

Epperson LA and Williams J. Biotherapy: Operationalizing delivery of care while managing risk. 2009:15(2);23-9.

Lima HA, Manning JO, Peters ME. Gaucher disease and enzyme replacement therapy. 1996;2(7):39-44. 

Lima HA. Cystic fibrosis: Advances in treatment. 1999;5(6):27-30.

Lima H. Looking down the pipeline: A biotech market update. 2000;7(1):14-9.

McCloskey WW, Stofko, JP. Human growth hormone therapy: An overview. 1996;2(5):40-44.

McCloskey WW, Stofko JP. Interferons in clinical practice: An update. 1996;3(3):31-37.

McKinnon B. Disease management for biotech drugs. 1996;2(9):31-39.

McKinnon BT. Biotechnology approaches the millennium-And managed care strategies keep pace. 1999;5(6):18-21.

McKinnon BT. Growth hormone: It's not just for kids. 1999;5(6):32-36.

McKinnon BT. Synagis®: A clinical overview. 2000;7(1):26-32.

Meaux N and Siefert L. Managing risk in the increasingly complex home care environment. 2009:15(2);36-40.

Mohler L. Looking down the pipeline: New drugs and biologicals for 2006. 2006:12(1):21-3.

Rigas M. Innovating Future Business Models and Relationships—Better Managing the High Cost of Biologics. 2008;14(5):17-21.

Rizk M. Hemophilia and biotechnology: An update. 1999;5(6):23-26.

Schumann K. Healthier babies: A valuable outcome. 2000;7(1):20-5.

Sullivan C. New parenteral drugs and biologics—2014: The essentials. Supplement to INFUSION.2015;21(4):S1-S16.

Zimay D and Erickson K. Pediatric patients with immune disorders: Utilization patterns and clinical outcomes. 1999;5(8):29-33.